Tango Therapeutics

Tango Therapeutics is a U.S.-based developer of novel cancer immunotherapies. The company is dedicated to leveraging advanced DNA sequencing and CRISPR gene-editing technologies to develop innovative cancer immunotherapies. Tango's genomics technology platform applies the principle of synthetic lethality, conducting large-scale genetic screening to identify synthetic lethal genes that interact with mutated genes, and developing targeted drugs to ultimately kill malignant cells. Since these drugs only target cancer cells with specific genetic mutations, they do not affect healthy cells.